The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease;Paraoksonaz geninde Leu-Met (55) ve Gln-Arg (192) polimorfizmleri ile koroner arter hastaliǧi arasindaki ilişki

Turk Kardiyoloji Dernegi Arsivi

Volumn 37, Issue 7, 2009, Pages 473-478

  Taşkiran, Pinar ^a   Çam, Sirri F ^a   Şekuri, Cevat ^b   Tüzün, Nurullah ^c   Alioǧlu, Emin ^c   Altintaş, Nuray ^d   Berdeli, Afig ^d  

^a CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

^b KENT HOSPITAL   (Turkey)

^c Central Hospital Izmir   (Turkey)

^d EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cholesterol, HDL metabolism; Coronary artery disease enzymology genetics; Esterases genetics; Genotype; Paraoxon metabolism; Polymerase chain reaction; Polymorphism, genetic

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; ESTERASE; GLUTAMINE; HIGH DENSITY LIPOPROTEIN; LEUCINE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; METHIONINE;

ADULT; ARTICLE; CODON; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ELECTROCARDIOGRAM; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; AMINO ACID SUBSTITUTION; ARGININE; ARYLDIALKYLPHOSPHATASE; CODON; CORONARY DISEASE; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; GLUTAMINE; HUMANS; LEUCINE; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 75649118616     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996;98:883-5.
2. Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001;42:146-50.
3. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 1995; 76:219-26.
4. La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993;87:25-34.
5. La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996;2:1186-7.
6. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473-80.
7. Motti C, Dessì M, Gnasso A, Irace C, Indigeno P, Angelucci CB, et al. A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphisms. Atherosclerosis 2001;158:35-40.
8. Aviram M. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5:381-6.
9. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.
10. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17:1067-73.
11. Ruiz J, Blanché H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-72.
12. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995;96:3005-8.
13. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997;17:3565-9.
14. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996;57:69-73.
15. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435-42.
16. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991;40:277-82.
17. Pati N, Pati U. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 1998;66:165-8.
18. Garin MC, James RW, Dussoix P, Blanché H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-6.
19. Aynacioǧlu AS, Kepekçi Y. The human paraoxonase Gln-Arg192 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 2000;74:33-7.
20. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
21. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
22. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124 Suppl:S1-9.
23. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
24. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95:774-82.
25. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101:2510-7.
26. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
27. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-3.
28. Qin Q, Li YL, Zhao FM, Wang H, Li Y, Cui RZ, et al. Association of paraoxonase polymorphisms and serum homocysteine thiolactone complex with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:803-7. [Abstract]
29. Sentí M, Tomás M, Vila J, Marrugat J, Elosua R, Sala J, et al. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonasel gene: the REGICOR study. Atherosclerosis 2001; 156:443-9.
30. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996; 126:299-303.
31. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
32. Aynacioǧlu AS, Cascorbi I, Mrozikiewicz PM, Nacak M, Tapanyigit EE, Roots I. Paraoxonase 1 mutations in a Turkish population. Toxicol Appl Pharmacol 1999; 157:174-7.